HealthEquity (HQY)
Market Price (3/14/2026): $78.0 | Market Cap: $6.7 BilSector: Health Care | Industry: Managed Health Care
HealthEquity (HQY)
Market Price (3/14/2026): $78.0Market Cap: $6.7 BilSector: Health CareIndustry: Managed Health Care
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 23% | Weak multi-year price returns2Y Excs Rtn is -36%, 3Y Excs Rtn is -54% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 22x, P/EPrice/Earnings or Price/(Net Income) is 35x |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 32%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 28% | ||
| Attractive yieldFCF Yield is 5.4% | ||
| Low stock price volatilityVol 12M is 42% | ||
| Megatrend and thematic driversMegatrends include Fintech & Digital Payments. Themes include Digital Payments, Online Banking & Lending, and Wealth Management Technology. |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 23% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 32%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 28% |
| Attractive yieldFCF Yield is 5.4% |
| Low stock price volatilityVol 12M is 42% |
| Megatrend and thematic driversMegatrends include Fintech & Digital Payments. Themes include Digital Payments, Online Banking & Lending, and Wealth Management Technology. |
| Weak multi-year price returns2Y Excs Rtn is -36%, 3Y Excs Rtn is -54% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 22x, P/EPrice/Earnings or Price/(Net Income) is 35x |
Qualitative Assessment
AI Analysis | Feedback
1. Significant Analyst Downgrades and Price Target Reductions.
Multiple financial institutions lowered their outlook on HealthEquity's stock value during the period. Goldman Sachs downgraded HealthEquity from "neutral" to a "sell" rating on January 9, 2026, setting a price target of $89.00. Concurrently, BTIG Research reduced its price target from $130.00 to $110.00 on February 18, 2026, contributing to the stock hitting a new 52-week low. Similarly, Jefferies lowered its price target for HQY to $108.00 from $120.00 on February 19, 2026, and Barclays also reduced its target from $118.00 to $110.00 on February 18, 2026.
2. Concerns over Declining HSA Cash Yields and Impact on Interest Income.
HealthEquity's business model is notably sensitive to fluctuations in interest rates, particularly the yield generated from its substantial HSA custodial cash. An updated HSA cash repricing schedule indicated that $4.5 billion of HSA cash is projected to reprice in fiscal year 2027 at a significantly lower average yield of 1.9%, compared to the current blended average yield of approximately 3.6%. This anticipated reduction in yields presents a notable near-term headwind to the company's interest income, even with efforts to mitigate this impact through Treasury forward contracts on roughly $2.3 billion of deposits.
Show more
Stock Movement Drivers
Fundamental Drivers
The -26.0% change in HQY stock from 11/30/2025 to 3/13/2026 was primarily driven by a -44.1% change in the company's P/E Multiple.| (LTM values as of) | 11302025 | 3132026 | Change |
|---|---|---|---|
| Stock Price ($) | 105.18 | 77.81 | -26.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,269 | 1,291 | 1.7% |
| Net Income Margin (%) | 11.5% | 14.9% | 29.3% |
| P/E Multiple | 62.4 | 34.9 | -44.1% |
| Shares Outstanding (Mil) | 87 | 86 | 0.6% |
| Cumulative Contribution | -26.0% |
Market Drivers
11/30/2025 to 3/13/2026| Return | Correlation | |
|---|---|---|
| HQY | -26.0% | |
| Market (SPY) | -3.1% | 28.0% |
| Sector (XLV) | -5.0% | 26.1% |
Fundamental Drivers
The -12.9% change in HQY stock from 8/31/2025 to 3/13/2026 was primarily driven by a -45.1% change in the company's P/E Multiple.| (LTM values as of) | 8312025 | 3132026 | Change |
|---|---|---|---|
| Stock Price ($) | 89.33 | 77.81 | -12.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,243 | 1,291 | 3.8% |
| Net Income Margin (%) | 9.8% | 14.9% | 51.7% |
| P/E Multiple | 63.6 | 34.9 | -45.1% |
| Shares Outstanding (Mil) | 87 | 86 | 0.8% |
| Cumulative Contribution | -12.9% |
Market Drivers
8/31/2025 to 3/13/2026| Return | Correlation | |
|---|---|---|
| HQY | -12.9% | |
| Market (SPY) | 3.0% | 37.1% |
| Sector (XLV) | 9.5% | 16.0% |
Fundamental Drivers
The -29.1% change in HQY stock from 2/28/2025 to 3/13/2026 was primarily driven by a -64.8% change in the company's P/E Multiple.| (LTM values as of) | 2282025 | 3132026 | Change |
|---|---|---|---|
| Stock Price ($) | 109.76 | 77.81 | -29.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,150 | 1,291 | 12.2% |
| Net Income Margin (%) | 8.4% | 14.9% | 76.8% |
| P/E Multiple | 99.0 | 34.9 | -64.8% |
| Shares Outstanding (Mil) | 87 | 86 | 1.4% |
| Cumulative Contribution | -29.1% |
Market Drivers
2/28/2025 to 3/13/2026| Return | Correlation | |
|---|---|---|
| HQY | -29.1% | |
| Market (SPY) | 12.4% | 46.4% |
| Sector (XLV) | 1.9% | 28.2% |
Fundamental Drivers
The 19.4% change in HQY stock from 2/28/2023 to 3/13/2026 was primarily driven by a 55.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282023 | 3132026 | Change |
|---|---|---|---|
| Stock Price ($) | 65.17 | 77.81 | 19.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 831 | 1,291 | 55.3% |
| P/S Multiple | 6.6 | 5.2 | -21.8% |
| Shares Outstanding (Mil) | 85 | 86 | -1.7% |
| Cumulative Contribution | 19.4% |
Market Drivers
2/28/2023 to 3/13/2026| Return | Correlation | |
|---|---|---|
| HQY | 19.4% | |
| Market (SPY) | 73.4% | 37.0% |
| Sector (XLV) | 23.3% | 20.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| HQY Return | -37% | 39% | 8% | 45% | -5% | -14% | 13% |
| Peers Return | 13% | -1% | 15% | 18% | -20% | -10% | 11% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -1% | 80% |
Monthly Win Rates [3] | |||||||
| HQY Win Rate | 42% | 58% | 42% | 67% | 42% | 33% | |
| Peers Win Rate | 53% | 48% | 57% | 65% | 45% | 27% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| HQY Max Drawdown | -43% | 0% | -17% | -0% | -20% | -20% | |
| Peers Max Drawdown | -15% | -16% | -5% | -5% | -32% | -14% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -2% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: WEX, VOYA, ADP, PAYX, FISV. See HQY Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/13/2026 (YTD)
How Low Can It Go
| Event | HQY | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -56.6% | -25.4% |
| % Gain to Breakeven | 130.3% | 34.1% |
| Time to Breakeven | 1,052 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -53.8% | -33.9% |
| % Gain to Breakeven | 116.4% | 51.3% |
| Time to Breakeven | 314 days | 148 days |
| 2018 Correction | ||
| % Loss | -48.2% | -19.8% |
| % Gain to Breakeven | 93.2% | 24.7% |
| Time to Breakeven | 1,866 days | 120 days |
Compare to WEX, VOYA, ADP, PAYX, FISV
In The Past
HealthEquity's stock fell -56.6% during the 2022 Inflation Shock from a high on 1/26/2021. A -56.6% loss requires a 130.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About HealthEquity (HQY)
AI Analysis | Feedback
```html- Mint.com for health expenses and savings.
- Fidelity for your health savings and investment accounts.
- ADP for managing health and commuter benefits.
AI Analysis | Feedback
- Technology-enabled Health Finance Platform: Cloud-based platforms empowering individuals to manage health savings, spending, and investment decisions, offering tools for comparison, personalized information, and wellness incentives.
- Health Savings Accounts (HSAs): Administration of tax-advantaged savings accounts used to pay for qualified medical expenses.
- Flexible Spending Accounts (FSAs): Administration of employer-sponsored plans allowing pre-tax contributions for healthcare or dependent care expenses.
- Health Reimbursement Arrangements (HRAs): Administration of employer-funded plans that reimburse employees for out-of-pocket medical expenses.
- Mutual Fund Investment Platform: A platform providing options for investing funds held in health savings accounts into various mutual funds.
- Automated Investment Advisory Services (Advisor): An online tool offering automated investment advice specifically for health savings accounts.
- COBRA Continuation Services: Administration of services enabling individuals to continue health coverage after certain qualifying events.
- Pre-tax Commuter Benefit Programs: Administration of programs allowing employees to use pre-tax earnings for qualified commuting expenses.
AI Analysis | Feedback
Major Customers of HealthEquity (HQY)
HealthEquity (HQY) sells its technology-enabled services platforms primarily to other companies, which then often make these services available to individuals (their employees or members). The provided company description does not list specific names of customer companies.
Based on the description, HealthEquity's major customers and partners fall into the following categories:
- Employers: HealthEquity provides platforms directly to employers for their employees to manage health savings and spending.
- Health Plans: The company works with a network of health plans, which likely integrate or offer HealthEquity's services to their members.
- Benefits Administrators: HealthEquity serves benefits administrators, who manage various employee benefits programs for other companies.
- Benefits Brokers and Consultants: These intermediaries recommend and facilitate the adoption of HealthEquity's solutions to employers and other organizations.
- Retirement Plan Record-keepers: The company partners with retirement plan record-keepers, integrating its health savings and investment options into broader financial wellness offerings.
AI Analysis | Feedback
- Axos Bank (AX)
AI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
The rapid advancement and integration of artificial intelligence (AI) and large language models (LLMs) into personal finance and healthcare management platforms pose an emerging threat. These technologies could enable new entrants, existing financial institutions, or major tech companies to offer highly personalized, automated, and proactive solutions for health saving and spending decisions, treatment cost comparisons, and HSA investment optimization. Such advanced AI-driven tools, potentially embedded directly into broader financial wellness platforms, electronic health records, or consumer-facing apps, could diminish the unique value proposition and necessity of HealthEquity's dedicated cloud-based platforms and advisory services by providing a more integrated and autonomous user experience.
AI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
nullLatest Trefis Analyses
Trade Ideas
Select ideas related to HQY.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | ADP | Automatic Data Processing | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 1.1% | 1.1% | -3.0% |
| 02062026 | HQY | HealthEquity | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | -3.7% | -3.7% | -7.9% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 85.21 |
| Mkt Cap | 18.6 |
| Rev LTM | 7,010 |
| Op Inc LTM | 2,237 |
| FCF LTM | 1,642 |
| FCF 3Y Avg | 1,612 |
| CFO LTM | 1,756 |
| CFO 3Y Avg | 1,703 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.1% |
| Rev Chg 3Y Avg | 7.5% |
| Rev Chg Q | 5.9% |
| QoQ Delta Rev Chg LTM | 1.4% |
| Op Mgn LTM | 26.3% |
| Op Mgn 3Y Avg | 25.9% |
| QoQ Delta Op Mgn LTM | -0.0% |
| CFO/Rev LTM | 25.5% |
| CFO/Rev 3Y Avg | 25.9% |
| FCF/Rev LTM | 20.0% |
| FCF/Rev 3Y Avg | 19.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 18.6 |
| P/S | 3.0 |
| P/EBIT | 11.3 |
| P/E | 19.0 |
| P/CFO | 13.6 |
| Total Yield | 8.7% |
| Dividend Yield | 1.4% |
| FCF Yield 3Y Avg | 5.2% |
| D/E | 0.3 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -3.4% |
| 3M Rtn | -18.2% |
| 6M Rtn | -21.9% |
| 12M Rtn | -21.6% |
| 3Y Rtn | -0.7% |
| 1M Excs Rtn | -1.0% |
| 3M Excs Rtn | -14.3% |
| 6M Excs Rtn | -25.0% |
| 12M Excs Rtn | -43.9% |
| 3Y Excs Rtn | -76.6% |
Comparison Analyses
Price Behavior
| Market Price | $77.81 | |
| Market Cap ($ Bil) | 6.7 | |
| First Trading Date | 07/31/2014 | |
| Distance from 52W High | -31.2% | |
| 50 Days | 200 Days | |
| DMA Price | $82.38 | $92.92 |
| DMA Trend | down | down |
| Distance from DMA | -5.6% | -16.3% |
| 3M | 1YR | |
| Volatility | 37.4% | 41.8% |
| Downside Capture | 105.54 | 85.94 |
| Upside Capture | -15.85 | 49.38 |
| Correlation (SPY) | 29.3% | 44.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.59 | 1.11 | 1.02 | 1.19 | 1.02 | 0.94 |
| Up Beta | -0.60 | 1.48 | 1.85 | 2.33 | 1.07 | 1.03 |
| Down Beta | 3.98 | 2.21 | 1.97 | 1.44 | 1.36 | 1.20 |
| Up Capture | 111% | -36% | -62% | 41% | 33% | 38% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 11 | 20 | 26 | 61 | 121 | 384 |
| Down Capture | 193% | 130% | 134% | 104% | 97% | 92% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 10 | 21 | 34 | 61 | 127 | 361 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HQY | |
|---|---|---|---|---|
| HQY | -19.3% | 41.9% | -0.40 | - |
| Sector ETF (XLV) | 5.0% | 17.5% | 0.12 | 28.3% |
| Equity (SPY) | 19.6% | 18.9% | 0.81 | 44.8% |
| Gold (GLD) | 71.9% | 26.3% | 2.05 | -12.7% |
| Commodities (DBC) | 19.3% | 17.3% | 0.89 | 13.1% |
| Real Estate (VNQ) | 6.2% | 16.3% | 0.19 | 30.0% |
| Bitcoin (BTCUSD) | -15.0% | 44.2% | -0.24 | 11.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HQY | |
|---|---|---|---|---|
| HQY | -0.1% | 39.5% | 0.11 | - |
| Sector ETF (XLV) | 7.5% | 14.5% | 0.33 | 19.0% |
| Equity (SPY) | 13.1% | 17.0% | 0.61 | 29.3% |
| Gold (GLD) | 24.1% | 17.3% | 1.14 | -12.3% |
| Commodities (DBC) | 11.2% | 19.0% | 0.47 | 10.4% |
| Real Estate (VNQ) | 4.8% | 18.8% | 0.16 | 12.6% |
| Bitcoin (BTCUSD) | 6.4% | 56.7% | 0.33 | 9.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HQY | |
|---|---|---|---|---|
| HQY | 13.0% | 44.6% | 0.44 | - |
| Sector ETF (XLV) | 10.1% | 16.5% | 0.50 | 38.3% |
| Equity (SPY) | 14.5% | 17.9% | 0.70 | 44.2% |
| Gold (GLD) | 14.4% | 15.6% | 0.77 | -11.2% |
| Commodities (DBC) | 8.6% | 17.6% | 0.40 | 17.9% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.23 | 30.3% |
| Bitcoin (BTCUSD) | 67.5% | 66.8% | 1.07 | 8.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 12/3/2025 | -3.0% | -3.0% | -3.2% |
| 9/2/2025 | 7.5% | 4.7% | 2.1% |
| 6/3/2025 | 9.0% | 3.3% | -1.9% |
| 2/18/2025 | 0.5% | -5.1% | -25.5% |
| 12/9/2024 | -5.6% | -7.8% | -0.7% |
| 9/3/2024 | 5.1% | -5.0% | 0.6% |
| 6/3/2024 | 2.7% | 7.0% | 2.9% |
| 2/21/2024 | 2.7% | 3.7% | 2.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 16 | 12 | 11 |
| # Negative | 7 | 11 | 12 |
| Median Positive | 3.6% | 3.8% | 2.9% |
| Median Negative | -5.6% | -6.5% | -6.1% |
| Max Positive | 11.6% | 10.3% | 14.7% |
| Max Negative | -24.6% | -27.4% | -25.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 10/31/2025 | 12/03/2025 | 10-Q |
| 07/31/2025 | 09/02/2025 | 10-Q |
| 04/30/2025 | 06/03/2025 | 10-Q |
| 01/31/2025 | 03/18/2025 | 10-K |
| 10/31/2024 | 12/09/2024 | 10-Q |
| 07/31/2024 | 09/03/2024 | 10-Q |
| 04/30/2024 | 06/03/2024 | 10-Q |
| 01/31/2024 | 03/22/2024 | 10-K |
| 10/31/2023 | 12/05/2023 | 10-Q |
| 07/31/2023 | 09/05/2023 | 10-Q |
| 04/30/2023 | 06/07/2023 | 10-Q |
| 01/31/2023 | 03/30/2023 | 10-K |
| 10/31/2022 | 12/08/2022 | 10-Q |
| 07/31/2022 | 09/08/2022 | 10-Q |
| 04/30/2022 | 06/08/2022 | 10-Q |
| 01/31/2022 | 03/31/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ladd, Delano | EVP, General Counsel | Direct | Sell | 12232025 | 94.72 | 1,500 | 142,080 | 7,007,291 | Form |
| 2 | Rosner, Elimelech | EVP, CHIEF TECHNOLOGY OFFICER | Direct | Sell | 12192025 | 95.45 | 10,959 | 1,046,090 | 4,366,298 | Form |
| 3 | Wellborn, Gayle Furgurson | Direct | Sell | 12162025 | 98.03 | 4,339 | 425,331 | 1,934,329 | Form | |
| 4 | Ladd, Delano | EVP, General Counsel | Direct | Sell | 11242025 | 104.56 | 1,500 | 156,840 | 7,892,084 | Form |
| 5 | Ladd, Delano | EVP, General Counsel | Direct | Sell | 10222025 | 92.07 | 1,500 | 138,105 | 7,087,457 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.